Association of Pharmacological Biomarkers with Treatment Response and Longterm Disability in Patients with Psoriatic Arthritis: Results from OUTPASS.

Abstract

OBJECTIVE:

To identify (1) whether tumor necrosis factor inhibitor (TNFi) drug levels/anti-drug antibodies (ADAb) are associated with treatment response and disability in patients with psoriatic arthritis (PsA); and (2) the factors associated with TNFi drug levels.

METHODS:

Patients were recruited from a national multicenter prospective cohort with longitudinal serum samples and 28-joint count Disease Activity Scores (DAS28)/Health Assessment Questionnaire (HAQ) measurement over 12 months.

RESULTS:

Adalimumab (ADA) drug levels were significantly associated with ΔDAS28 (β 0.055, 95% CI 0.011-0.099; p = 0.014) and inversely with HAQ over 12 months (β -0.022, 95% CI -0.043 to -0.00063). Factors significantly associated with ADA drug levels were ADAb levels and body mass index.

CONCLUSION:

Drug level testing in ADA-initiated PsA patients may be useful in determining treatment response/disability over 12 months.

• Authors: Meghna Jani, Hector Chinoy, Anne Barton, for OUTPASS
• Journal: The Journal of rheumatology (J Rheumatol) Vol. 47 Issue 8 Pg. 1204-1208 (08 01 2020) ISSN: 0315-162X [Print] Canada
• PMID: 31371650 (Publication Type: Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)

Chemical References

• Antirheumatic Agents
• Biomarkers, Pharmacological
• Tumor Necrosis Factor-alpha

Topics

• Antirheumatic Agents (therapeutic use)
• Arthritis, Psoriatic (drug therapy)
• Biomarkers, Pharmacological
• Humans
• Prospective Studies
• Tumor Necrosis Factor-alpha